With Patholytix 3.0, Deciphex overcomes one of the last barriers to full-scale adoption of digital pathology.
For the first time, users can review and score non-clinical studies on a single platform. The benefit is faster pathology reviews, with less risk of error.
The pathology module in existing data management systems is only designed for work with glass slides. Pathologists must purchase a Whole Slide Image Viewer as well as their LIMS system to perform digital reviews.
In primary reviews, pathologists would then view the slide on their WSI Viewer and input findings on LIMS. Since there is no syncing between the two systems, human errors can arise with data input.
A primary review pathologist would then have to export this report and send it to the peer review pathologist. Next, the peer reviewer would look back and forth between the two systems to find the corresponding findings for the slide he/she is viewing (another potential point of human error).
There’s no risk of human error with data input. There’s less work involved since users don’t have to manually match a slide with its findings in the LIMS systems.
Prior to Patholytix 3.0, most LIMS providers only accommodated for toxicology studies (safety assessment studies). Patholytix 3.0 offers flexible scoring templates and data capture support for drug discovery studies such as TCR, TTC and DRF. No other LIMS can support data capture for such studies.
This is the first time ever that a digital pathology platform has enabled the review and scoring of drug discovery studies. Now, users can review these studies digitally, while reaping the benefits of a more efficient workflow.
In Patholytix 3.0, users can score directly on the image they are reviewing (geolocated findings). This capability is not possible in any other LIMS or digital pathology platform.
This makes the peer review process quicker as a peer review pathologist knows precisely where to look in the image for the abnormality.
With Patholytix 3.0, users can score the same study from two different locations and the new scores will be reflected immediately. This is a workflow that could not be possible before.
The quicker the review is complete, the quicker a decision can be made on the safety of the drug.
Patholytix allows users to keep their study findings, be they for glass, digital or hybrid studies, all in one place.
This allows you to begin your review immediately using the glass slides while waiting for slides to be scanned. This also means you don’t have to depend on any LIMS to record the findings from your glass slides. You can input these findings in the same place as for your digital slides.
Once primary review is complete, results can be shared with partner organisations instantaneously.
Patholytix ends long wait times for shipped slides and large volumes of Customs documentation.
With Patholytix, there is no sorting, counting, or checking slides for breaks. Findings are inputted to Patholytix (associated with its WSI). The primary review pathologist emails the peer review pathologist once complete. The peer review pathologist begins review.
Not only is the current LIMS with a built-in pathology module not fit for purpose, but subscription is more expensive. Replacing expensive LIMS pathology modules, the Patholytix 3.0 solution is more cost-effective, and technically better.
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin
1012 95th Street, Naperville,
Exeter Science Park Centre,
6 Babbage Way, Exeter